:quality(85)//cloudfront-us-east-1.images.arcpublishing.com/infobae/2VFK5JZWLRGZBBUA2QEWYAHVIY.jpg "The regulatory agency of the European Union began to examine the Russian vaccine Sputnik V against the coronavirus")
The European Medicines Agency (EMA) began on Thursday a process of “continuous review”, a real-time analysis, of data on the safety, efficacy and quality of the Russian vaccine against covid-19 Sputnik-V, the process that could lead to the authorization of the use of this drug in the European Union (EU).
It’s a statement, the European regulator stressed that the decision to take the step “is based on the results of laboratory studies and clinical studies in adults” that the drug developer has shared with European scientists from the EMA, information that is already being analyzed by its experts at its headquarters in Amsterdam.
For their part, coinciding with the EMA’s announcement, the Russian authorities said they were willing to supply vaccines to 50 million Europeans from June,
“After approval by the EMA, we would be able to supply vaccines for 50 million Europeans from June 2021”said in a statement Kirill Dmitriyev, director of the Russian sovereign wealth fund, which has contributed to the development of the Sputnik V vaccine.
“Sputnik V can make an important contribution to saving millions of lives in Europe”, dijo Dmitriyev.
“Those who work together on vaccines should put politics aside. Cooperation with the EMA is the perfect example that joining forces is the only way to end the pandemic ”, he added, underlining that the injectable has already been approved by some 40 countries.
These last weeks there was a back and forth of statements among those responsible for the Russian vaccine, who claimed that they had sent all the information for the drug to be approved by the EMA, and the European regulatory body, which assured that they had not received anything.
The Russian vaccine was greeted with skepticism by western countries but is convincing the experts, especially after the publication of results in the scientific journal The Lancet, according to which, Sputnik V will be effective in 91.6% of cases symptomatic of covid-19.